Datapoint: CMS Finalizes Aduhelm Coverage Decision

CMS on April 7 finalized its narrow coverage of Biogen’s controversial Alzheimer’s drug Aduhelm, limiting coverage to Medicare beneficiaries enrolled in clinical trials. The monoclonal antibody is the only drug approved to treat Alzheimer’s, and holds covered or better status for just 24% of all insured lives in the U.S.

SOURCE: MMIT Analytics, as of 4/12/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 23

Datapoint: Centene Pledges Nearly $1B for Affordable Housing

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 22

Datapoint: CMS Extends Medicaid Redetermination Deadline

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 21

Datapoint: Aetna Shut Out of Medicaid Contract Awards

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today